QUIBIM Precision Prostate (qp-Prostate) vs ProstatID
AI Verdict
Choose QUIBIM Precision Prostate (qp-Prostate) if…
Choose QUIBIM Precision Prostate if your radiology department requires a comprehensive AI solution for detailed prostate MRI interpretation, including automated segmentation, advanced image quality assessment, and integrated support for PI-RADS compliant reporting. This tool is ideal for institutions seeking to streamline workflows and directly support fusion biopsy and focal therapy planning with robust on-premise or cloud-integrated deployment options.
View QUIBIM Precision Prostate (qp-Prostate) →Choose ProstatID if…
Choose ProstatID if your primary goal is to enhance prostate cancer screening, detection, and diagnosis across a broad patient population, particularly focusing on reducing false positives through AI-powered image interpretation and 3D modeling. This cloud-based SaaS solution is well-suited for health systems looking for a scalable, per-click cost model to integrate AI into their prostate cancer diagnostic pathway.
View ProstatID →When choosing between QUIBIM Precision Prostate (qp-Prostate) and ProstatID, physicians should consider their existing infrastructure and specific workflow needs. qp-Prostate excels in comprehensive prostate MRI interpretation, offering automated segmentation, AI-driven lesion detection, and PI-RADS compliant reporting. It also provides advanced features like automated image quality assessment (AI-QUAL™) and support for fusion and focal therapy planning. Its deployment flexibility, with both on-premise and cloud-integrated options, makes it suitable for various health system sizes and preferences.
ProstatID, on the other hand, is a SaaS, cloud-based solution focused on enhancing diagnostic accuracy and reducing false positives in prostate cancer screening, detection, and diagnosis through AI-powered image interpretation and 3D modeling. The key practical difference lies in their deployment and feature sets. qp-Prostate offers a broader range of analytical tools and deployment choices, while ProstatID is a purely cloud-based, per-click cost model. Physicians with a need for extensive on-premise control or a wider array of integrated planning tools might lean towards qp-Prostate. Conversely, those prioritizing a streamlined, cloud-native solution with a pay-per-use model for screening and diagnosis may find ProstatID more appealing.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | QUIBIM Precision Prostate (qp-Prostate) | ProstatID |
|---|---|---|
| Pricing | Contact vendor | Not publicly available |
| Deployment | On-premise (standard workstation compatible) and cloud-integrated for large health systems. | SaaS (Software as a Service), cloud-based, secure VPN connection, PACS to PACS integration. |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
QUIBIM Precision Prostate (qp-Prostate)QUIBIM Precision Prostate emphasizes seamless integration with PACS and fusion biopsy systems, along with being 'standard workstation compatible' and offering PI-RADS compliant structured reporting. This focus on fitting into existing radiology workflows and familiar reporting mechanisms suggests a highly usable tool for radiologists. ProstatID, while SaaS-based for easy access, mentions a 'secure VPN connection' which might imply a slightly more involved setup for some users.
Clinical Value
QUIBIM Precision Prostate (qp-Prostate)Both tools demonstrate strong clinical value with FDA clearance and reported improvements in diagnostic accuracy. However, QUIBIM Precision Prostate offers unique features like AI-QUALu2122 for automated MRI image quality assessment, which addresses a critical factor in diagnostic reliability, and explicitly supports the stratification of aggressive prostate cancer lesions. It also highlights training algorithms with pathology data as ground truth, and an increase in sensitivity for radiologists. ProstatID boasts a 93.6% AUROC and significant reductions in false positives and read times.
Pricing & Value
ProstatIDProstatID provides more transparency regarding its pricing model, stating a 'per-click cost; percentage of sales' and a 'low, predictable per-study fee,' with zero upfront hardware investment. It also quantifies potential cost savings, such as hundreds of thousands annually for a facility by reducing unnecessary biopsies. While QUIBIM Precision Prostate aims to reduce healthcare costs, its pricing is simply listed as 'Contact vendor,' offering less insight into its value proposition.
Enterprise Readiness
QUIBIM Precision Prostate (qp-Prostate)QUIBIM Precision Prostate offers flexible deployment options, including on-premise and cloud-integrated solutions tailored for large health systems, providing adaptability to diverse IT infrastructures. Its partnerships, such as with Ferrum Health for secure and scalable deployment, further enhance its enterprise readiness. ProstatID is a SaaS-only solution, which, while convenient, offers less deployment flexibility for complex enterprise environments.
Innovation
QUIBIM Precision Prostate (qp-Prostate)While ProstatID claims to be 'North America's first and only FDA-Cleared AI software for the Screening, Detection and Diagnosis of Prostate Cancer,' QUIBIM Precision Prostate showcases several distinct innovations. Its AI-QUALu2122 feature for automated MRI image quality assessment is an industry-first, addressing a foundational challenge in image interpretation, and its algorithms are trained with pathology data as ground truth, also noted as an industry-first for certain markets. The mention of future predictive capabilities also indicates ongoing innovation.
Support & Docs
QUIBIM Precision Prostate (qp-Prostate)QUIBIM (Tool A) demonstrates a more structured approach to support, explicitly mentioning 'Consulting and training' services, a dedicated 'Customer service' department, and an 'Info Hub' with webinars and scientific publications. While ProstatID (Tool B) highlights quick IT setup assistance and ease of use, it does not detail the same breadth of ongoing support and educational resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | QUIBIM Precision Prostate (qp-Prostate) | ProstatID |
|---|---|---|
| Tool Name | QUIBIM Precision Prostate (qp-Prostate) | ProstatID |
| Company | QUIBIM S.L. | ScanMed |
| Automated Segmentation / 3D Modeling | Automated prostate segmentation (peripheral zone, transitional/central zone, seminal vesicles) | 3D modeling |
| AI-driven Lesion Detection / Diagnosis Focus | AI algorithm for detection and stratification of aggressive prostate cancer lesions | AI software for prostate cancer screening, detection, and diagnosis using MRI |
| Structured Reporting / Image Quality Assessment | PI-RADS compliant structured reporting; AI-QUALu2122 for automated prostate MRI image quality assessment (PI-QUAL v2 guidelines); Automated diffusion and perfusion analysis (ADC map, synthesized b-1400s/mm2) | Not specified |
| Specific Therapy Planning Support | Support for fusion biopsy planning; Support for focal therapy planning | Not specified |
Videos
Demos, reviews, and walkthroughs featuring QUIBIM Precision Prostate (qp-Prostate) and ProstatID.
Frequently Asked Questions
More Comparisons
More matchups featuring QUIBIM Precision Prostate (qp-Prostate) or ProstatID
Backers
Who funded each tool's parent company.